Oliveri Valentina
Dipartimento di Scienze Chimiche, Università Degli Studi di Catania, Catania, Italy.
Front Mol Biosci. 2022 Mar 4;9:841814. doi: 10.3389/fmolb.2022.841814. eCollection 2022.
Conventional cancer therapies suffer from severe off-target effects because most of them target critical facets of cells that are generally shared by all rapidly proliferating cells. The development of new therapeutic agents should aim to increase selectivity and therefore reduce side effects. In addition, these agents should overcome cancer cell resistance and target cancer stem cells. Some copper ionophores have shown promise in this direction thanks to an intrinsic selectivity in preferentially inducing cuproptosis of cancer cells compared to normal cells. Here, Cu ionophores are discussed with a focus on selectivity towards cancer cells and on the mechanisms responsible for this selectivity. The proposed strategies, to further improve the targeting of cancer cells by copper ionophores, are also reported.
传统的癌症治疗方法存在严重的脱靶效应,因为它们大多针对细胞的关键方面,而这些方面通常为所有快速增殖的细胞所共有。新型治疗药物的开发应旨在提高选择性,从而减少副作用。此外,这些药物应克服癌细胞耐药性并靶向癌症干细胞。一些铜离子载体已在这方面展现出前景,这得益于其内在的选择性,即与正常细胞相比,它们能优先诱导癌细胞发生铜死亡。在此,我们将讨论铜离子载体,重点关注其对癌细胞的选择性以及造成这种选择性的机制。还报告了为进一步提高铜离子载体对癌细胞的靶向性而提出的策略。